AMARANTUS BIOSCI INC (OTCQB: AMBS) stock climbed 4.17% to $0.0875 after the company today reported that upon further analysis of the data reported on January 9th, 2013, the striatal reinnervation (densitometry) data produced in the 6 hydroxydopamine (6-OHDA) neurorestoration rat model of Parkinson’s disease for MANF at 36ug achieved a statistically significant improvement over the data produced for GDNF, with a P value of 0.047.
Additionally, the company, on Jan. 31, announced it has secured an additional $1.4 million of financing commitments through an amendment of the initial Convertible Note with Dominion Capital.
Will AMBS Move Higher After Today’s Sudden Selling Activities? Don’t Miss The Free Trend Analysis here http://beststocksdaily.com/p2/index.php?company=AMBS
Rexahn Pharmaceuticals, Inc. (NYSE: RNN) stock gained 8.27% to $0.357 in the early hour. Maxim Group initiated coverage on shares of Rexahn in a research report released on Jan. 30. The firm issued a buy rating and a $1.50 price target on the stock.
Additionally, the company, on Jan. 22, announced that it has appointed Dr. Peter D. Suzdak as its new Chief Executive Officer (CEO). He succeeds Dr. Chang Ahn, who will move into the role of Chief Scientist and will remain as Chairman of the Board.
Vringo, Inc. (NYSE: VRNG) stock fell 0.94% to $3.16. The company, last week, said it has filed a lawsuit against Microsoft Corp. alleging infringement over relevance filtering technology patents. The software developer for cellphones said the lawsuit alleges infringement of patents entitled "Collaborative/Adaptive Search Engine" and "Information Filter System and Method for Integrated Content-Based and Collaborative/Adaptive Feedback Queries," respectively.
Additionally, A Virginia federal judge last week denied a bid by ringtone maker Vringo Inc. to add to its $30 million patent infringement verdict against Google Inc., rejecting its argument that he should not have limited damages to the past year.
Hemispherx BioPharma, Inc (NYSE: HEB) shares dropped 6.20% to $0.262 in the early hour. On Feb. 1, The Rosen Law Firm reminds investors of the important February 22, 2013 lead plaintiff deadline in the class action filed on behalf of investors who purchased the securities of Hemispherx Biopharma during the period from March 19, 2012 through December 17, 2012.
New Gold Inc. (USA) (NYSE: NGD) shares jumped 0.30% to $10.16. The 52 week trading range for the company is $7.13 - $12.84. The shares of the company declined 13% in the last one year. The company is engaged in gold mining and related activities, including acquisition, exploration, extraction, processing and reclamation.
YM BioSciences Inc. (USA) (NYSE: YMI) stock gained 0.17% to $2.93 after the company, on Jan.3 1, announce that, at the special meeting (the "Meeting") of shareholders of the Company (the "YM Shareholders") held earlier today, the YM Shareholders approved the previously announced plan of arrangement (the "Arrangement") involving the Company, Gilead Sciences, Inc. ("Gilead") and 3268218 Nova Scotia Limited, a wholly-owned subsidiary of Gilead (the "Purchaser").
Beststocksdaily’s team is engaged in providing valuable and updated news information on U.S. stocks on a regular basis. Beststocksdaily’s instant stock news on Major Gainers, Hot Stocks and various other stocks, guides investors in making the wise stock market investments decision. To Get Instant updates in the inbox, readers are advised to sign up for free at Beststocksdaily.com.
The assembled information disseminated by beststocksdaily.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. beststocksdaily.com does expect that investors will buy and sell securities based on information assembled and presented in beststocksdaily.com. PLEASE always do your own due diligence, and consult your financial advisor.
1419 Westwood Blvd Los Angeles, CA